ESMO Gynecological Cancers Congress | Conference

Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer

July 3rd 2024

Dostarlimab plus chemotherapy demonstrated a meaningful overall survival improvement in primary endometrial cancer, regardless of mismatch repair status.

Dostarlimab/Chemo/Niraparib Generates PFS Benefit in Primary/Recurrent Endometrial Cancer

June 25th 2024

Dostarlimab/chemotherapy/niraparib elicited favorable PFS outcomes across several subgroups in primary advanced or recurrent endometrial cancer.

Rucaparib Maintenance Elicits Continued PFS Benefit Across Newly Diagnosed Ovarian Cancer Subgroups

June 24th 2024

First-line rucaparib maintenance therapy maintained a PFS benefit vs placebo at 4 years of follow-up in newly diagnosed advanced ovarian cancer.

Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer

June 21st 2024

First-line lenvatinib plus pembrolizumab demonstrated antitumor activity across various histologic subtypes in advanced or recurrent endometrial cancer.

Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer

June 21st 2024

Durvalumab plus chemotherapy, followed by durvalumab maintenance with or without olaparib, improved responses in advanced endometrial cancer.

Mirvetuximab Soravtansine Elicits Benefits in Ovarian Cancer Regardless of Dose Modifications

June 21st 2024

Mirvetuximab soravtansine generated PFS, OS, and ORR improvements in patients with ovarian cancer who required dose modifications in the MIRASOL trial.

Durvalumab Combo Before Olaparib-Based Maintenance Sustains PFS Benefit in BRCA-Unmutated Ovarian Cancer

June 20th 2024

Durvalumab/chemotherapy/bevacizumab, then durvalumab/bevacizumab/olaparib maintenance, sustained a PFS benefit in BRCA-unmutated advanced ovarian cancer.

ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma

June 20th 2024

ROCSAN step 1 did not meet its primary end point of 16-week response rate with niraparib or dostarlimab/niraparib in endometrial/ovarian carcinosarcoma.

Vibostolimab Plus Pembrolizumab Fails to Boost Efficacy in Pretreated PD-L1+ Cervical Cancer

June 20th 2024

Vibostolimab plus pembrolizumab was not superior to pembrolizumab monotherapy in pretreated PD-L1–positive advanced cervical cancer.